Cambridge Cognition CEO Matthew Stork Excited over potential for growth (Interview)

Cambridge Cognition Holdings plc (LON:COG), a technology company which develops and markets patient-focused solutions to better assess brain health, has announced its unaudited preliminary results for the year ended 31 December 2021. Highlights The Company delivered

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, will announce its preliminary results for the year ended 31 December 2021 on 12 April 2022. Cambridge Cognition is a technology company

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a contract worth just over £1 million with a top 10 pharmaceutical company to provide digital

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the appointment of Panmure Gordon (UK) Limited as the Company’s Nominated Adviser and Joint Broker with immediate effect. The

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has been awarded contracts worth £2.1 million to provide cognitive assessments, electronic diaries, and third-party hardware for

Cambridge Cognition Holdings plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a positive trading update for the year ended 31 December 2021. Unaudited highlights for the year ended 31 December 2021

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has been awarded contracts for two clinical trials by a top 20 pharmaceutical company to assess the pro-cognitive

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a contract worth over £500,000 to provide electronic clinical outcome assessments to support a major

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has secured a contract for an additional schizophrenia clinical trial worth £1.0m. The revenue from this contract is

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has secured a contract for a further sizeable schizophrenia trial with an existing customer.  Cambridge Cognition has

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced its unaudited interim results for the six months ended 30 June 2021. The Company had a strong and profitable first

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced a positive trading update for the six months ended 30 June 2021. The Company enjoyed a strong performance in the

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a £1 million contract as the cognitive assessment partner for a late phase cancer trial.

Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced the completion of the spin-out of Monument Therapeutics Limited, a drug development company applying digital phenotyping to central nervous